MARKET

ORIC

ORIC

Oric Pharmaceuticals, Inc.
NASDAQ
7.79
+0.09
+1.17%
After Hours: 7.70 -0.09 -1.16% 19:47 03/14 EDT
OPEN
7.71
PREV CLOSE
7.70
HIGH
7.96
LOW
7.71
VOLUME
462.44K
TURNOVER
--
52 WEEK HIGH
15.59
52 WEEK LOW
6.33
MARKET CAP
553.30M
P/E (TTM)
-4.2487
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ORIC last week (0303-0307)?
Weekly Report · 4d ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Barchart · 03/07 15:30
ORIC Pharmaceuticals Reports Progress in Cancer Trials
TipRanks · 03/06 04:14
Weekly Report: what happened at ORIC last week (0224-0228)?
Weekly Report · 03/03 09:22
Guggenheim Reiterates Buy on ORIC Pharmaceuticalsto Buy
Benzinga · 02/26 16:26
Positive Outlook for Oric Pharmaceuticals: Buy Rating Affirmed on Promising ORIC-944 Updates and Strategic Refocus
TipRanks · 02/26 11:18
ORIC PHARMACEUTICALS INC <ORIC.O>: JP MORGAN RAISES TARGET PRICE TO $22 FROM $21
Reuters · 02/26 05:28
Oric Pharmaceuticals (ORIC) Gets a Buy from Oppenheimer
TipRanks · 02/26 04:35
More
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

Webull offers ORIC Pharmaceuticals Inc stock information, including NASDAQ: ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.